Lv1
64 积分 2025-03-05 加入
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
9小时前
已完结
Evolving therapeutic landscape of advanced hepatocellular carcinoma
1个月前
已完结
Evolution of Systemic Therapy in Advanced Hepatocellular Carcinoma
1个月前
已完结
Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025
1个月前
已完结
Evolving therapeutic landscape of advanced hepatocellular carcinoma
1个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
3个月前
已完结
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
3个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
3个月前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
3个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
3个月前
已完结
皖公网安备34019202002308
